Format: 2 videos + 1 pdf
Size: 33.1 GB
Release Year : 2023

The 3CT Meeting 5th Edition – Critical Care Clinical Trialists Workshop is a high-level international scientific meeting focused on the development, design, conduct, ethics, and interpretation of clinical trials in critical care and intensive care medicine.

Following the success of previous Cardiogenic Shock Workshops, the 2023 program brought together leading experts from North America, Europe, and Asia, along with representatives from regulatory agencies, government institutions, academia, industry, and patient communities.

The meeting provided a focused think-tank environment for discussing emerging evidence, innovative trial methodologies, regulatory considerations, and challenges in developing clinical trials involving critically ill patients.

About the 3CT Meeting

The Critical Care Clinical Trialists (3CT) Workshop follows the model of the CVCT Workshop and is designed as a limited-attendance, expert-level forum for international exchange and collaboration.

The program brings together professionals from diverse backgrounds, including:

• Intensivists
• Pulmonologists
• Cardiologists
• Emergency physicians
• Clinical trialists
• Principal investigators
• Biostatisticians
• Academic researchers
• Pharmaceutical and biotechnology professionals
• Regulatory experts
• Government research institutions
• Patient representatives

The workshop addresses clinical trials involving drugs, medical devices, biomarkers, and other emerging approaches in intensive care medicine.

Scientific Program

Session 1: Cardiogenic Shock Studies

The opening session examines the evolving landscape of cardiogenic shock research and the clinical trials and registries shaping the field.

Key topics include:

• The importance of clinical trials in cardiogenic shock
• ECLS and cardiogenic shock studies
• The role and value of clinical registries
• Safety considerations in cardiogenic shock research
• Heterogeneity among cardiogenic shock patients
• DPP3 modulators and emerging therapeutic approaches
• Nursing perspectives in cardiogenic shock research
• Patient perspectives
• Regulatory and research considerations
• Panel discussion on the future of cardiogenic shock studies

Session 2: Acute Respiratory Distress Syndrome

This session explores recent developments in acute respiratory distress syndrome (ARDS) research and the implications of emerging evidence for clinical trial design.

Topics include:

• The 2023 global definition of ARDS
• Lessons from COVID-19 clinical trials
• Changes in clinical trial design during the COVID-19 pandemic
• Research and institutional support for ARDS studies
• Recent ARDS clinical trial findings
• PETAL and related ARDS research programs
• Precision medicine approaches in COVID-19
• Complement-targeted therapies and emerging treatments
• Regulatory considerations for novel ARDS therapies
• Industry perspectives
• Patient perspectives
• Panel discussion on the future of ARDS research

Session 3: Worsening Heart Failure

The worsening heart failure session focuses on identifying patients at risk, improving treatment strategies, and developing meaningful endpoints for clinical trials.

Key areas include:

• Risk stratification in acute heart failure
• Safe early discharge of emergency department patients
• Early initiation of SGLT2 inhibitors
• Prevention of worsening heart failure after hospitalization
• Assessment and measurement of congestion
• Congestion-related primary endpoints in clinical trials
• Early implementation of guideline-directed medical therapy
• Implementation of clinical guidelines
• Industry perspectives on heart failure research
• Patient perspectives
• Regulatory and clinical trial considerations
• Panel discussion on improving outcomes in acute heart failure

Session 4: Artificial Intelligence in Critical Care

This session examines the growing role of artificial intelligence (AI) in critical care and the methodological challenges involved in evaluating AI-based technologies.

Topics include:

• Moving AI from proof of concept to proof of value
• Clinical trial design for AI algorithms
• AI-supported clinical decision-making
• Collective human intelligence and imitation learning
• Algorithmic bias in critical care
• Identification and mitigation of AI-related bias
• AI applications in peri-operative care
• Home-based heart failure diagnosis using ultrasound and AI
• Industry perspectives on AI in healthcare
• Regulatory and scientific considerations
• Panel discussion on AI as a transformative technology in critical care

Session 5: Novelties in Sepsis and Septic Shock

The sepsis and septic shock program examines emerging therapies, trial designs, and endpoint strategies in one of the most challenging areas of critical care research.

Part A: Preventing Organ Dysfunction Matters

Topics include:

• Lessons from recent sepsis clinical trials
• Prevention of organ dysfunction
• Toxin-neutralizing therapies
• Personalized immunotherapy
• Precision approaches to sepsis treatment
• Emerging therapeutic strategies
• Regulatory and clinical trial considerations
• Panel discussion on preventing organ dysfunction

Part B: Intravenous Therapies Remain Essential

This section explores emerging intravenous therapies and their evaluation in patients with septic shock.

Key topics include:

• Recent phase IIb clinical trial findings
• Phase III trial design in septic shock
• Precision medicine approaches to septic shock
• Emerging therapies targeting septic shock
• Clinical trial development and implementation
• Regulatory considerations
• Industry perspectives
• Panel discussion on the future of intravenous therapies

Part C: Primary Endpoints in Critical Care Trials

The final session examines one of the fundamental methodological questions in modern critical care research: how should clinical trials measure treatment success?

Topics include:

• Primary endpoints in critical care clinical trials
• Organ dysfunction as a clinical trial endpoint
• Mortality as an outcome measure
• Combining organ dysfunction and mortality outcomes
• Improving survival as a primary research objective
• Selection of clinically meaningful endpoints
• Industry perspectives on trial endpoints
• Regulatory considerations
• Panel discussion on endpoint selection in critical care trials

Key Areas Covered

The 3CT Meeting 5th Edition provides extensive coverage of contemporary critical care research, including:

• Critical care clinical trials
• Intensive care research
• Clinical trial design
• Trial methodology
• Cardiogenic shock
• ECLS and shock research
• Acute respiratory distress syndrome
• ARDS clinical trials
• Sepsis and septic shock
• Worsening heart failure
• Acute heart failure
• Precision medicine
• Personalized immunotherapy
• Emerging drug therapies
• Medical devices
• Biomarkers
• Artificial intelligence in critical care
• AI clinical trials
• Algorithmic bias
• Regulatory science
• FDA and EMA considerations
• Clinical trial endpoints
• Organ dysfunction
• Mortality outcomes
• Patient-centered research
• Industry-sponsored research
• Multidisciplinary critical care research

International Expert Think-Tank

A defining feature of the 3CT Workshop is its high-level, multidisciplinary format. Rather than focusing solely on traditional presentations, the meeting encourages active discussion and exchange among experts from clinical medicine, research, regulatory agencies, government institutions, industry, and patient communities.

This structure allows participants to examine difficult questions surrounding clinical trial development and identify opportunities to improve the quality, relevance, and efficiency of critical care research.

Included Materials

This educational collection includes the conference materials and continuous video recordings covering the scientific sessions.

The available content includes:

• Agenda PDF
• June 8 conference video
• June 10 conference video

The continuous recordings include the individual presentations and panel discussions featured throughout the program.

Who Is This For?

The 3CT Meeting is particularly relevant to professionals involved in critical care medicine and clinical research, including:

• Intensivists
• Critical care physicians
• Pulmonologists
• Cardiologists
• Emergency physicians
• Clinical trialists
• Principal investigators
• Biostatisticians
• Clinical researchers
• Academic investigators
• Pharmaceutical and biotechnology researchers
• Regulatory professionals
• Medical device researchers
• Healthcare policymakers
• Research fellows
• Professionals involved in intensive care clinical trials

Product Overview

The 3CT Meeting 5th Edition – Critical Care Clinical Trialists Workshop provides an in-depth educational resource on the challenges and opportunities shaping modern critical care clinical research.

From cardiogenic shock and ARDS to sepsis, heart failure, artificial intelligence, precision medicine, and clinical trial endpoints, the program examines how innovative research can generate stronger evidence and improve outcomes for critically ill patients.

The workshop is particularly valuable for professionals seeking a deeper understanding of clinical trial design, methodology, regulatory considerations, emerging therapies, and evidence generation in intensive care medicine.